Disclaimer

Some of the compounds featured are experimental antiretroviral agents. For prescribing and all other information please contact the relevant manufacturer.

This programme also discusses clinical development activities investigating unapproved dosing schedules of currently registered antiretroviral agents. Please refer to local prescribing information for approved indications, dosing regimens and other relevant information.

The views expressed are those of the presenters and are not necessarily those of F.Hoffmann-La Roche Ltd. or MediTech Media Ltd